Muzzio M. Plasma Pharmokinetics of LMP400 in Rats and Dogs.
Antony S, Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Pommier Y, The indenoisoquinoline nonCamptothecin topoisomerase I inhibitors: update and perspectives. Read more
Candeil L. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan‐treated metastases. Stenvang J. Targeting the topoisomerase I enzyme in cancer cells with acquired resistance to SN-38. Jensen NF. Characterization of DNARead more
Burton JH. NCI Comparative Oncology Program Testing of Non-Camptothecin Indnoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.Read more
Kummar S. Clinical and pharmacologic evaluation of two dosing schedules of indenothecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.Read more
Tang SW. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.Read more
Murai J. SLFN11 Blocks Stress Replication Forks Independently of ATR. Pommier Y. Indotecan (LMP400), Imidotecan (LMP776) and LMP744: a new class of non-camptothecin TOP1 inhibitors selective for cancer cells with homologous recombination deficiencies and highRead more
Aris S. Potentiation of the novel Topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor, AZD7762.Read more
Gibson Oncology,LLC is composed of proven academic researchers and bio tech entrepreneurs who are excited to be developing effective and safer novel oncology drugs to treat resistant cancers with a focus on children.
Leave a Comment